Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
US7109026B2 · kind B2 · utility
8Cited by
0References
5Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Jan 10, 2002 |
| Grant date | Sep 19, 2006 |
| Priority date | — |
| Expiry date | Aug 31, 2023 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a use of a MHC class II ligand, such as CD4 and LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer-immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen able to induce an antigen-specific immune response together with an effective amount of a MHC class II ligand wherein said MHC class II ligand is present as an adjuvant-like agent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.